European monoclonal antibodies market is estimated to grow at a CAGR of 7.2% during the forecast period. The increasing prevalence of cancer and rising approvals for monoclonal antibodies are some pivotal factors encouraging market growth. As per the World Health Organization (WHO), in Europe, there were nearly 4.2 million new cancer incidences reported in 2018. The most common forms of cancer reported in the region include breast cancer (12.4%), colorectum (11.8%), lung (11.1%), prostate (10.6%), bladder (4.7%), and other cancers (49.4%). Monoclonal antibodies act as one of the potentially used immune system proteins produced in the lab, which is highly useful in cancer treatment. These antibodies are developed naturally by the body and support the immune system to detect germs that cause disease, including viruses and bacteria, and point them for destruction. Monoclonal antibodies detect specific targets and thereby work to destroy cancer cells. 

Visit for Global Monoclonal Antibodies Market Report at: https://www.omrglobal.com/industry-reports/monoclonal-antibodies-market

European monoclonal antibodies market is segmented based on source and application. Based on the source, the market is classified into murine, chimeric, human, and humanized. Humanized monoclonal antibodies are expected to have potential application as it has major benefits compared to original mouse monoclonal antibodies. The monoclonal antibodies immunogenicity is reduced and the serum half-life of the monoclonal antibodies in humans is significantly enhanced. It is an established technique to reduce the immunogenicity of monoclonal antibodies from xenogeneic sources (usually rodent). In addition, it is used to improve the activation of the human immune system. Based on the application, the market is classified into cancer, infectious diseases, auto-immune diseases, inflammatory diseases, and others. 

Based on the countries, the market is classified into the UK, Germany, France, Spain, Italy, and the Rest of Europe. The UK is estimated to hold a potential share in the market owing to the rising preference for monoclonal antibodies therapy as targeted and immunotherapy coupled with the increasing cancer incidences in the country. As per the World Health Organization (WHO), the number of new cancer incidences reported in the country was 446,942 in 2018. This results in an increasing demand for monoclonal antibodies such as bevacizumab (Avastin), trastuzumab (Herceptin), rituximab (Mabthera), and pertuzumab (Perjeta) in the country.

Some key players in the country include AstraZeneca plc, Pfizer Inc., Sitryx Therapeutics Ltd., Orchard Therapeutics plc, and Mylan N.V. These companies are adopting some potential strategies such as product launches and partnerships and collaborations, to accelerate their market share. For instance, In May 2020, AstraZeneca declared that it will partner with ArcherDX, a genomic analysis company engaged in precision oncology. Under the partnership, AstraZeneca will utilize ArcherDX personalized cancer monitoring which aims to detect minimal residual disease in patients having early-stage non-small cell lung cancer (NSCLC). This assay will be utilized in the Phase III MERMAID-1 trial of AstraZeneca which indicates to assess the outcome of adjuvant treatment with Imfinzi (durvalumab). It is a human monoclonal antibody along with chemotherapy versus chemotherapy alone on disease-free survival. 

Research Methodology

The market study of the European monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. European Monoclonal Antibodies Market Research and Analysis by Source
2. European Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the European monoclonal antibodies market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the European monoclonal antibodies market.
• Insights about market determinants which are stimulating the European monoclonal antibodies market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.